Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pNGVL4a-CRTE6E7L2
- Development stage
- Unknown
- Lead developer
- Johns Hopkins University
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
pNGVL4a-CRTE6E7L2 is a therapeutic DNA vaccine developed by Johns Hopkins University in collaboration with Ichor Medical Systems for the treatment of HPV16-positive high-grade cervical intraepithelial neoplasia (CIN 2/3). The vaccine utilizes the pNGVL4a plasmid vector to encode a fusion protein comprising calreticulin (CRT) linked to the HPV16 E6 and E7 oncoproteins and the L2 minor capsid protein. This construct is designed to enhance the presentation of HPV antigens to the immune system, specifically inducing potent HPV-specific CD8+ T cell responses against the E6 and E7 oncoproteins and generating neutralizing antibodies against the L2 protein. The vaccine is administered intramuscularly using the TriGrid Electroporation Device, which significantly improves cellular uptake of the DNA and subsequent immune activation compared to conventional injection methods.
- Other names
- pNGVL4a-CRT-E6-E7-L2pNGVL-4a-CRT-E6-E7-L2pNGVL 4a-CRT-E6-E7-L2CRT/E6/E7/L2 DNA vaccineHPV16 E6/E7/L2 DNA vaccine
02
Targets
HPV16 E7 (Human papillomavirus 16 E7 protein)HPV16 E6 oncoproteinHPV16 L2CALR (Calreticulin)
Beyond the preview
Go deeper on pNGVL4a-CRTE6E7L2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pNGVL4a-CRTE6E7L2.